Gladius Capital Management LP Eq Rx, Inc. Transaction History

Gladius Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Dec 18, 2023	BUY	$1.66 - $2.31 $4,219 - $5,872	2,542 Added 21.9%	14,149 $31,000
Q3 2023 Oct 10, 2023	BUY	$1.66 - $2.31 $4,219 - $5,872	2,542 Added 21.9%	14,149 $32,000
Q2 2023 Dec 18, 2023	SELL	$1.61 - $1.96 $4,092 - $4,982	-2,542 Reduced 17.97%	11,607 $21,000
Q2 2023 Aug 08, 2023	SELL	$1.61 - $1.96 $4,614 - $5,617	-2,866 Reduced 19.8%	11,607 $22,000
Q1 2023 Dec 18, 2023	BUY	$1.8 - $2.83 $583 - $916	324 Added 2.29%	14,473 $28,000
Q1 2023 May 09, 2023	BUY	$1.8 - $2.83 $26,051 - $40,958	14,473 New	14,473 $29,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.